Literature DB >> 8856607

The antiphospholipid/cofactor syndromes.

D Alarcón-Segovia, A R Cabral.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8856607

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  4 in total

1.  The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment.

Authors:  M Schwartz; M Rochas; E Toubi; B Sharf
Journal:  J Psychiatry Neurosci       Date:  1999-09       Impact factor: 6.186

2.  Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides.

Authors:  M Blank; Y Shoenfeld; S Cabilly; Y Heldman; M Fridkin; E Katchalski-Katzir
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-beta2-glycoprotein I antibodies.

Authors:  L La Rosa; G Covini; C Galperin; L Catelli; N Del Papa; G Reina; A Morabito; G Balestrieri; A Tincani; M E Gershwin; P L Meroni
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

4.  Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Authors:  L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.